Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine
- PMID: 4004417
Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine
Abstract
Apomorphine, a dopamine receptor agonist, physostigmine, an anticholinesterase agent and pilocarpine, a cholinergic receptor agonist, produced yawning in rats, with the most effective doses being 0.25 mg/kg, 0.2 mg/kg and 4 mg/kg, respectively. The yawning induced by these drugs is characterized by differences in direction of head moving, tongue protruding and duration of the yawn. The apomorphine-induced yawn was characterized by a slow and wide opening of the mouth with the head moving mainly downward and with a marked protrusion of the tongue. The apomorphine-induced yawn was 3.6 sec in duration. Physostigmine elicited a similar yawn to that seen with apomorphine, except for moving of the head in the upward direction. The pilocarpine-induced yawn was characterized by the head moving forward with a high frequency but without tongue protrusion and lasted 1.8 sec. The frequency of physiological yawning was low, but the behavioral posture was almost similar to that of physostigmine-induced yawning. The characteristics of yawns induced by these agents were unchanged at all doses of the drugs. Different doses altered the frequency of yawning. After pretreatment with mecamylamine, the apomorphine- and physostigmine-induced tongue protruding was inhibited and the duration of the yawning induced by the both drugs was shortened. The results suggest that the behavioral features of yawning induced by apomorphine, physostigmine and pilocarpine differ from one another, and that physiological yawning as well as physostigmine-induced yawning may be mediated by endogenous acetylcholine which stimulates both muscarinic and nicotinic receptors.
Similar articles
-
Modification of apomorphine-, physostigmine- and pilocarpine-induced yawning after long-term treatment with neuroleptic or cholinergic agents.Arch Int Pharmacodyn Ther. 1984 Oct;271(2):180-8. Arch Int Pharmacodyn Ther. 1984. PMID: 6150689
-
Muscarinic and nicotinic effects on yawning and tongue protruding in the rat.Pharmacol Biochem Behav. 1984 Aug;21(2):297-300. doi: 10.1016/0091-3057(84)90229-6. Pharmacol Biochem Behav. 1984. PMID: 6541344
-
[Age-related modification of dopaminergic-cholinergic neuronal interaction in rats].Yakubutsu Seishin Kodo. 1988 Dec;8(4):443-51. Yakubutsu Seishin Kodo. 1988. PMID: 3250156 Japanese.
-
Non-human primates: a comparative developmental perspective on yawning.Front Neurol Neurosci. 2010;28:63-76. doi: 10.1159/000307082. Epub 2010 Mar 26. Front Neurol Neurosci. 2010. PMID: 20357464 Review.
-
Yawning in the history of psychiatry.Hist Psychiatry. 2021 Dec;32(4):449-461. doi: 10.1177/0957154X211029772. Epub 2021 Jul 19. Hist Psychiatry. 2021. PMID: 34278821 Review.
Cited by
-
Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning.Psychopharmacology (Berl). 1988;95(1):34-7. doi: 10.1007/BF00212762. Psychopharmacology (Berl). 1988. PMID: 3133698
-
The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.Psychopharmacology (Berl). 1988;95(1):29-33. doi: 10.1007/BF00212761. Psychopharmacology (Berl). 1988. PMID: 2898789